Security Snapshot

FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) Institutional Ownership

CUSIP: 31447P100

13F Institutional Holders and Ownership History from Q3 2017 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

105

Shares (Excl. Options)

16.31MFull value: 16,314,161 · shares · 30 Jun 2026

Price

$10.75

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+82,614
Value change
+$14,034,301
Number of holders
105
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
35,203,113
SEC-reported price per share
$10.65
Insider filing price
$10.65
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 31447P100.
  • 105 institutions reported positions in Q2 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 90 to 105 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $99.64MFull value: $99,641,723 · USD · 31 Mar 2026
    to
    $175.07MFull value: $175,068,095 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 105 institutions filings for Q2 2026.

Open SEC evidence

Security key

31447P100

13F reference period

Q2 2026

13F holders

105

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
FENC
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Rosalind Advisors, Inc. 9.6% +8.9% $35,704,330 +$3,007,850 3,321,333 +9.2% Rosalind Advisors, Inc. 30 Jun 2026
Sonic Fund II, L.P. 8.2% $21,503,685 2,799,959 Kam Lawrence 31 Dec 2025
HIRSCHMAN ORIN 7.1% +23% $26,624,332 +$5,516,987 2,499,421 +26% Orin Hirschman 30 Sep 2026
Solas Capital Management, LLC 5.4% -26% $20,310,684 -$6,372,944 1,889,366 -24% Solas Capital Management, LLC 30 Jun 2026
DG Capital Management, LLC 4.1% $6,342,597 1,114,692 DG Capital Management, LLC 31 Dec 2024
As of 30 Jun 2026, 105 institutional investors reported holding
16.31MFull value: 16,314,161 · shares · 30 Jun 2026
shares of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC). This represents 46% of the company’s total
35.2MFull value: 35,203,113 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
42%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Rosalind Advisors, Inc. 9.1% 3,188,001 +9.6% 13% $34,271,011
AIGH Capital Management LLC 7.1% 2,486,038 +25% 2.4% $26,724,908
Solas Capital Management, LLC 5.4% 1,889,366 -24% 11% $20,310,685
BlackRock, Inc. 4.9% 1,727,069 +26% 0% $18,565,992
AWM Investment Company, Inc. 3.3% 1,160,296 +61% 1.1% $12,473,182
VANGUARD CAPITAL MANAGEMENT LLC 2.4% 839,306 -6.4% 0% $9,022,540
Prospect Capital Advisors, LLC 1.4% 497,800 2.4% $5,351,350
STATE STREET CORP 1.2% 426,004 +19% 0% $4,579,543
GEODE CAPITAL MANAGEMENT, LLC 1.1% 402,566 +8.3% 0% $4,327,584
JANE STREET GROUP, LLC 0.66% 233,877 0% $2,514,178
Potomac Capital Management, Inc. 0.64% 224,400 0% 1.8% $2,412,300
MORGAN STANLEY 0.63% 221,920 +5.1% 0% $2,385,640
VANGUARD PORTFOLIO MANAGEMENT LLC 0.57% 199,998 +19% 0% $2,149,979
NORTHERN TRUST CORP 0.48% 167,922 +10% 0% $1,805,162
MARSHALL WACE, LLP 0.39% 138,758 0% $1,491,651
RENAISSANCE TECHNOLOGIES LLC 0.38% 134,200 0% $1,442,650
Nuveen, LLC 0.37% 131,482 +116% 0% $1,413,432
Trexquant Investment LP 0.34% 119,122 +130% 0.01% $1,280,562
CenterBook Partners LP 0.34% 118,582 0.06% $1,274,757
Lion Point Capital, LP 0.32% 112,434 0% 5.8% $1,208,666
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.31% 108,005 +30% 0.02% $1,161,054
Cornerstone Capital, Inc. 0.3% 105,000 0% 0.1% $1,128,750
XTX Topco Ltd 0.27% 93,866 +515% 0.01% $1,009,060
AQR CAPITAL MANAGEMENT LLC 0.26% 92,889 +285% 0% $998,557
WELLINGTON MANAGEMENT GROUP LLP 0.24% 84,548 0% $908,892

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
37
Headline period
Q2 2026
Rows shown
1-25 of 37
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 517,741 $5,513,001 +$4,432,646 $10.65 19
2026 Q2 16,314,161 $175,068,095 +$14,034,301 $10.75 105
2026 Q1 16,201,228 $99,641,723 +$2,876,181 $6.15 90
2025 Q4 15,538,506 $119,646,530 +$11,219,093 $7.70 96
2025 Q3 13,863,242 $129,757,954 +$2,614,052 $9.36 83
2025 Q2 13,599,927 $112,877,891 +$2,365,581 $8.30 77
2025 Q1 13,390,166 $81,552,976 -$1,522,792 $6.09 68
2024 Q4 16,048,764 $101,424,546 +$7,283,101 $6.32 64
2024 Q3 14,931,283 $74,650,166 +$2,539,947 $5.00 62
2024 Q2 14,360,522 $87,742,748 -$6,402,237 $6.11 62
2024 Q1 14,487,904 $161,105,911 -$6,099,282 $11.12 64
2023 Q4 15,010,968 $168,423,713 +$8,238,895 $11.22 55
2023 Q3 14,291,968 $107,334,991 +$1,444,870 $7.51 54
2023 Q2 14,066,767 $124,212,045 +$9,438,707 $8.83 54
2023 Q1 13,040,023 $108,481,973 +$4,197,539 $8.32 53
2022 Q4 12,451,231 $119,532,387 -$8,641,346 $9.60 42
2022 Q3 11,367,575 $92,077,143 +$913,826 $8.10 29
2022 Q2 11,273,521 $63,103,949 -$835,989 $5.63 24
2022 Q1 11,437,604 $64,049,354 +$542,291 $5.60 24
2021 Q4 11,346,536 $49,924,524 -$2,427,096 $4.40 26
2021 Q3 11,649,016 $109,719,412 -$3,040,624 $9.42 30
2021 Q2 12,077,739 $88,042,799 -$14,218,632 $7.29 36
2021 Q1 14,373,653 $89,259,363 -$593,443 $6.21 49
2020 Q4 14,462,317 $107,736,409 +$5,043,456 $7.45 48
2020 Q3 13,830,913 $83,811,378 -$1,125,208 $6.06 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .